First Niagara Bank’s Teva Pharmaceuticals TEVA Stock Holding History

First Niagara Bank’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,395	Closed	-$222K	–	194
2015 Q4	$222K	Buy	+3,395	New	+$210K	0.06%	181
2015 Q2	–	Sell	-4,181	Closed	-$261K	–	245
2015 Q1	$261K	Sell	4,181 -61	-1%	-$3.55K	0.06%	199
2014 Q4	$244K	Sell	4,242 -14,385	-77%	-$801K	0.05%	208
2014 Q3	$1M	Sell	18,627 -100	-0.5%	-$5.3K	0.21%	102
2014 Q2	$982K	Sell	18,727 -1,050	-5%	-$53.7K	0.2%	106
2014 Q1	$1.04M	Sell	19,777 -8,815	-31%	-$407K	0.21%	105
2013 Q4	$1.15M	Sell	28,592 -2,559	-8%	-$101K	0.22%	99
2013 Q3	$1.18M	Sell	31,151 -525	-2%	-$20.5K	0.25%	93
2013 Q2	$1.24M	Buy	+31,676	New	+$1.23M	0.26%	88

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

First Niagara Bank's TEVA Position: Q1 2016 in Review

First Niagara Bank sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 3,395 shares — an estimated $222K sold.

First Niagara Bank first reported a position in TEVA in Q2 2013 and held it in 9 quarters. The position peaked at $1.24M in Q2 2013. 837 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

First Niagara Bank reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
First Niagara Bank sold 3,395 Teva Pharmaceuticals shares in Q1 2016, an estimated $222K.
First Niagara Bank first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 9 quarters.
First Niagara Bank's Teva Pharmaceuticals position peaked at $1.24M in Q2 2013.
837 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on First Niagara Bank's 13F filing for Q1 2016, filed 13 May 2016.